Veozah the New Drug for Menopausal Hot Flashes + SkinVive the New Dermal Filler — Xtalks Life Science Podcast Ep. 111
XTalks
MAY 25, 2023
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
52 
Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved
XTalks
SEPTEMBER 14, 2022
Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. ng of the core active ingredient. Bringing Daxxify into Offices.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Consumer health innovation – where passion and science meet
pharmaphorum
DECEMBER 9, 2021
We are combining our life-science expertise and ingenuity to leverage digital technologies to accelerate innovation, applying a digital first mindset to how we innovate by using data to analyse and predict what our consumers need.”. “We Self care, skin health and technology innovation.
SkinVive by Juvéderm: The New Dermal Filler Coming to the US
XTalks
MAY 22, 2023
It’s an extremely important factor I consider in my therapeutic process of restoring their natural beauty and appearance,” said Macrene Alexiades, MD, PhD, dual US-EU board-certified dermatologist, SkinVive by Juvéderm lead investigator and author of the clinical trial published in Dermatologic Surgery.
Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends
XTalks
AUGUST 2, 2023
2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. 2022 R&D Spend: In 2022, Merck KGaA (Life Science and Healthcare divisions only) spent €2.02
Let's personalize your content